Jul 12, 2021 8:00am EDT OPKO Health Licenses Oligonucleotide Therapeutics Platform to CAMP4 Therapeutics
Jun 22, 2021 7:39am EDT BioReference Laboratories Announces First COVID-19 Testing Program for Cruise Industry
Jun 21, 2021 8:03am EDT OPKO Health to Develop and Commercialize RAYALDEE® in Greater China with Nicoya Therapeutics
Jun 17, 2021 7:00am EDT OPKO Health Announces Sale of its Sterile Fill and Finish Manufacturing Facility in Ireland
May 24, 2021 7:30am EDT OPKO Health Reports Transfer of Licensed Rights to RAYALDEE® in Japan to Vifor
May 07, 2021 1:33pm EDT OPKO Health Enters into Exchange Agreements with Certain 4.5% Convertible Senior Noteholders
Apr 28, 2021 4:05pm EDT OPKO Health Reports 2021 First Quarter Business Highlights and Financial Results